How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about talazoparib

Marketing authorisation indication

2.1

Talazoparib (Talzenna, Pfizer) is indicated 'in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated'.

Price

2.3

The list price of talazoparib is £1,655 for a 30-pack of 0.25 mg capsules (excluding VAT; BNF online accessed July 2025).

2.4

The company has a commercial arrangement. This makes available to the NHS with a discount and it would have also applied to this indication if had been recommended. The size of the discount is commercial in confidence.

Carbon Reduction Plan

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Pfizer will be included here when guidance is published.